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Rapamycin was discovered more than thirty years ago from a soil sample from the island of Rapa Nui. It was
isolated from Streptomyces hygroscopicus and initial characterization focused on its antifungal activities.
Subsequent characterization showed that it has immunosuppressive properties and has been used successfully to
reduce organ rejection with kidney transplantation. Rapamycin has proven to be a versatile compound with several
seemingly unrelated properties, including antifungal, immunosuppressive, and anticancer. The National Cancer
Institute (NCI) Developmental Therapeutics Program demonstrated that rapamycin inhibited cell growth in tumor
cell lines. These observations stimulated research to explore the underlying mechanism of anti-tumor activities. Cell
growth inhibition involves binding to the mammalian Target of Rapamycin (mTOR). The mTOR signaling pathway is
critical to cell growth, proliferation, and survival and rapamycin inhibits these hallmark processes of cancer. Binding
of growth factors activates mTOR signaling, which in turn leads to downstream phosphorylation of protein kinases,
e.g., p70S6 kinase and lipid kinases in the phosphorylation of phosphoinositides. Understanding of mTOR signaling
provided the biological basis for targeted chemotherapeutics development, including several rapamycin analogues
for treating breast and other cancers.
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Introduction
Breast cancer is the second most commonly diagnosed
cancer, after skin cancer, among U.S. women. In 2012,
227,000 new cases have been reported [1]. Recent
developments in computed tomography imaging have
improved the early detection of breast cancer, when
treatment is most effective [2]. Concomitant with the
technological development is the explosion of research
findings on the molecular mechanisms of breast cancer.
As a result, mechanism-based approaches have become
increasingly used as strategies for therapeutic develop-
ments. This confluence of technology development in
early diagnosis and improved therapeutics has led to a
decline in breast cancer death in recent years, although
death rates are still higher than all types of cancer other
than lung cancer [3].Correspondence: setob@mail.nih.gov
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Bioengineering, 9000 Rockville Pike, Building 31, Room 1C14, Bethesda, MD
20892, USA
© 2012 Seto; licensee Springer. This is an Open
License (http://creativecommons.org/licenses/b
medium, provided the original work is properlyThis report describes a tale of discovery that reinforces
the serendipitous nature of basic research and the no-
tion that discoveries may lead to unanticipated outcomes
in other disciplines. In this particular story, the isolation
of the bacterium Streptomyces hygroscopicus from a soil
sample three decades ago on a remote island led to in-
tense, multifaceted research that changed the way breast
cancer is treated. The identification of rapamycin from
Streptomyces hygroscopicus as an antifungal agent,
through being an immune inhibitor to being an effective
anticancer drug, demonstrates a research continuum
driven by clinical observations that were critical in the
elucidation of the mTOR pathway. Rapamycin provided
the stimulus for research on the complex and pivotal
mTOR pathway that transmits signals through which it
controls a range of vital biological processes. The dissec-
tion of the molecular networks of interacting signaling
pathways has led to improved understanding of the tran-
scription, protein synthesis, and metabolic processes that
underpin oncogenic transformation. Such knowledge has
led to therapeutic developments that yielded targetedAccess article distributed under the terms of the Creative Commons Attribution
y/2.0), which permits unrestricted use, distribution, and reproduction in any
cited.
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trogen and/or progesterone receptor positive, endocrine
therapies offer treatments that interfere with the signal-
ing pathway involved in cell growth and proliferation.
Two targeted therapeutic examples include aromatase
inhibitors, which interfere with estrogen production, and
tamoxifen, which interferes with estrogen binding to the
receptor. For patients who are HER-2 positive, targeted
therapies with HER2 antibodies, such as trastuzumab
and lapatinib, offer possible treatment options [4].
This review will focus on the mammalian Target of
Rapamycin (mTOR) pathway and also provide a per-
spective on translational research, from the chemical
and pharmacologic characterization of rapamycin to the
molecular mechanisms of breast cancer, ending with
clinical applications and treatments.
Discovery of rapamycin
Rapamycin, (also known by its generic name, Sirolimus)
is a natural product isolated from Streptomyces hygro-
scopicus, found on the island of Rapa Nui in 1972 [5].
Structural studies showed that it is similar to an anti-
biotic FK506 [6], a macrolide lactone. Studies following
its discovery showed rapamycin to exhibit multiple prop-
erties, including antibacterial activity, antifungal (anti-
Candida), and immunosuppressive effects. It inhibits
antigen-induced T cell and B cell proliferation and anti-
body formation. The latter finding has significant clinical
implications as rapamycin was developed into an im-
munosuppressant drug for patients following organ
transplantation. It was approved by the U.S. Food and
Drug Administration (FDA) as a prophylaxis for renal re-
jection. Wyeth Pharmaceuticals marketed Rapamune as
an immunosuppressant for use in conjunction with corti-
costeroids and cyclosporine to prevent kidney rejection
[7].
The discovery that rapamycin was an immunosup-
pressant might not have led to testing its potential as a
viable tumor suppressor if it were not for the research
of Dr. Suren Sehgal at Ayerst Research Laboratories,
Montreal, where rapamycin was isolated in 1972. Intui-
tively one would have thought that an immunosuppres-
sive compound would prevent an immune response
against tumor cells and therefore would not be a likely
anticancer drug. But Dr. Sehgal observed that this
compound appeared to possess novel properties beyond
its immunosuppressive activities [8]. He sent a sample
of rapamycin to the National Cancer Institute (NCI)
Developmental Therapeutics Program and requested
anti-tumor activity screening. As a standard screening
protocol, NCI initially tested compounds for growth in-
hibition against a limited number of human tumor cell
lines. If the compound showed inhibition against one
of more of these cell lines, it would be further testedfor growth inhibition or killing of one or more of the
NCI standard 60 human tumor cell lines with varying
concentrations of the compounds. Approximately 2% of
the 2500 compounds tested annually proceed to the
next stages of in vivo tests in xenographs in mice.
Against the 60 tumor cell line panel, rapamycin was
found to inhibit the growth of a number of tumor cell
lines including mammary, colon 26, B16 43 melanocar-
cinma, and EM ependymoblastoma [9]. Based on these
test results, NCI advanced rapamycin as a priority
drug.
Mammalian Target of Rapamycin (mTOR)
Following the NCI finding of anti-tumor activities in
rapamycin, numerous reports were published confirming
its inhibitory effect on cell growth [10,11] in several
organisms: Saccharomyces cerevisiae [12], Drosophila
[13,14], Caenorhabditis elegans [15], fungus [16], plants
[17], and mammals [18]. In these organisms, the inhibi-
tory mechanism involves binding to the target proteins,
collectively named Target of Rapamycin (TOR) [12]. The
specifics of the inhibitory mechanisms differ with the
various organisms. However, there are consistent obser-
vations that these proteins are highly conserved evolu-
tionarily [19]. TOR protein sequences from eukaryotes
share approximately 40% to 60% homology and several
structural motifs are conserved [20]. Human TOR pro-
tein showed even higher homology in the primary se-
quence with other mammalian TORs (mTOR), 95% [21].
Biochemical studies showed that mTOR forms two
complexes: mTORC1 and mTORC2 [22]. The
mTORC1 complex is composed of mTOR, Raptor
(regulatory-associated protein of mTOR) and mLST8/
GβL (mammalian lethal with Sec13protein8/G-protein
β-subunit-like protein), PRAS40 (proline-rich AKT sub-
strate of 40kDa) and DEPTOR (DEP-domain-containing
mTOR-interacting protein) [23]. mTORC1 is the catalytic
kinase complex. The component proteins of mTORC1
contain a large number of conserved motifs, including
those that are essential for protein-protein interactions.
This observation, together with the finding of kinase activ-
ity in this complex, suggests that this complex may be the
nexus for mTOR signaling. Rapamycin does not inhibit
the mTORC1 kinase activity directly. It initially forms a
complex with the FK506 binding protein (FKPB12), which
in turn binds mTORC1 [24-27].
The observation that TOR proteins are conserved
across the broad spectrum of organisms, from simple
eukaryotes to mammals, led to subsequent investigations
of TOR functions. The assumption that TORs might
play a vital role in survival is well-grounded, as these
proteins, with some variations structurally, are con-
served through evolution. Thus, it is concluded that
TOR functions are not only fundamental to survival, but
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role in cell survival, the TOR pathway receives signaling
inputs from insulin, growth factors and nutrients. The
TOR pathway is central to regulating cell growth (cell
size or mass) and proliferation (cell number), and
responding to stress such as nutrient starvation (glucose
or amino acids) that ultimately affects cellular energy
levels [13,14,28,29]. Underpinning mTOR’s involvement
in cell growth are the associated processes including
transcription, protein translation, and cell cycle regula-
tion from G1 to S phase. Given the importance of these
biological processes, it should come as no surprise that
the TOR pathway is involved in many disease processes.
While a comprehensive review of mTOR’s role in disease
processes is beyond the scope of this report, it is import-
ant to understand the mTOR signaling mechanism as it
underlies many disease processes and has served to
guide cancer therapeutic development and treatment.
mTOR signaling pathway and regulatory network
mTOR is a serine/threonine kinase of the phosphatidyli-








Figure 1 mTOR pathway.through the PI3K and Akt/PKB pathway [30]. Growth
factors (insulin-like growth factor 1 (IGF-1), insulin,
epidermal growth factor, vascular epithelial growth fac-
tor) when bound to the cell surface receptors, activate
the intracellular signaling of the PI3K/Akt pathway
(Figure 1). The downstream effect of this activation is
the phosphorylation of p70S6 Kinase and 4EBP1 [31].
An additional downstream effect is an increased phos-
phorylation of serine2448 on mTOR. Indication that
mTOR signaling is involved in oncogenic transform-
ation stemmed from studies of Akt mutants with kin-
ase activity but failed to phosphorylate p70S6 kinase
and 4EBP1. These mutants failed to transform chicken
embryo fibroblast cells [32]. mTOR-driven phosphoryl-
ation of key proteins is an intricate balance of regula-
tory switches that determine which mRNA will be
translated as a result of mTOR kinase activity. For ex-
ample, mTOR phosphorylation of p70S6 kinase leads
to downstream phosphorylation of the 40S ribosomal
protein S6, resulting in increased translation from
mRNAs that contain the 50-terminal oligopyrimidine
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synthesis and protein synthesis generally. Activation of
4EBP1 translation initiation factor, on the other hand,
leads to increased translation from mRNAs with 50-
untranslated regions such as those for cyclin D1 and c-
myc, which are crucial to cell cycling (Figure 2). These
examples illustrate mTOR’s role in regulating protein
biosynthesis by phosphorylating key proteins.
Another important process that is regulated by PI3K
signaling involves lipid kinases in the phosphorylation of
phosphoinositides. Activated PI3K leads to increased
production of phosphatidylinositol 3, 4, 5-triphosphate
(PIP3), which in turn recruits Akt for cell growth, prolif-
eration, and survival. These are hallmarks for cancers.
Conversely, PIP3 is negatively regulated by a tumor sup-
pressor, phosphatase and tensin homolog (PTEN) via
dephosphorylation. Phosphorylation is also inhibited by
rapamycin. It should come as no surprise, due to the sig-
nificance of the regulatory activities of the PI3K/Akt
pathway and its interaction with mTOR, that dysfunc-
tion of these signaling activities would alter cellular
functions, as observed in most cancers. Dysfunction can
also stem from genetic mutations. Mutations or gene
amplification are found in components of the PI3K/Akt
pathway in a large number of tumors [34]. A remarkably
large percentage of breast cancer, greater than 70%, was
found to have mutations in the genes involved in this
pathway [35].
mTOR inhibitors target breast cancer mechanism
Recognition of rapamycin’s anti-tumor target of the
mTOR pathway led to the development of analogues ofX
p70S6 Kinase 





Figure 2 Rapamycin inhibition.rapamycin as chemotherapeutic agents against solid
tumor types, including breast cancer. However, there are
substantial challenges with the pharmacokinetics of
rapamycin due to its lipophilic chemistry [32]. Various
formulations have been tested to improve its poor water
solubility and bioavailability for clinical applications.
Currently three analogues of rapamycin have been devel-
oped: Temsirolimus (Wyeth/Pfizer) [36], Deforolimus or
Ridaforolimus (Merck/Ariad) and Everolimus, manufac-
tured by Novartis [35,37,38]. Although these analogues
differ in their formulation and bioavailability, the mech-
anism of inhibition is the same, binding to the mTORC1
target, thereby arresting cell cycling at the G1 phase.
Temsirolimus was approved by the FDA for treating
renal cell carcinoma. For metastatic breast cancer, tem-
sirolimus in combination with letrozole was used in a
phase III trial, but the combination of drugs did not
show benefit over letrozole (aromatase inhibitor) alone
[39].
As an mTORC1 inhibitor, everolimus reduces Akt and
mTOR signaling, resulting in increased apoptosis. Evero-
limus alone or in combination with tamoxifen has been
evaluated in postmenopausal breast cancer patients with
hormone receptor positive, HER2 negative metastatic
breast cancer. Bachelot et al. [40] reported a 46% reduc-
tion in risk of progression with the combination of tam-
oxifen and everolimus vs. tamoxifen alone. Risk of death
was also reduced, by 55%, in the combined drug treat-
ment group. For patients whose disease has progressed
despite treatment with trastuzumab and chemotherapy,
it has been shown that the addition of everolimus to
trastuzumab and chemotherapy provides a 19% to 44%eIF4E





5’ capped mRNAs 
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compounds discussed in this review is listed in Table 1.
It is postulated that there are cross-talks between sig-
naling pathways: hormone signaling and the PI3K/Akt/
mTOR pathways. Hormone receptor positive tumors
rely on hormone-mediated signaling for growth. How-
ever, as hormone treatment continues, adaptive upregu-
lation of growth factor mediated signaling, such as the
PI3K/Akt/mTOR pathway, reinforces cross-talks leading
to constitutive activation of the cell growth pathways,
rendering the patients resistant to hormone treatment
[35,44-47]. Everolimus, by inhibiting the PI3K/Akt/
mTOR signaling, has been shown to restore hormone
sensitivity [48]. Everolimus was recently approved by the
FDA for use in combination with Aromasin for treating
advanced hormone-receptor positive HER2-negative
breast cancer [49].
Translational research: a public-private partnership
The discovery of rapamycin in 1972 was serendipitous
but this fortuitous beginning has led to immense impact
on medicine. Over the subsequent decades, its activities
have been widely investigated. It has been found to be
an exceptionally “versatile” molecule in that it possesses
antifungal, immunosuppressive, and anticancer activities.
These characteristics attracted investigators from differ-
ent disciplines to pursue basic research on the pharma-
cology of rapamycin, synthetic chemistry to produce
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Lapatinib EGFR HER2 positive
breast cancerclinical research on therapeutic development and disease
treatment. However, a single individual, Dr. Suren Sehgal,
is noteworthy for his keen observation that rapamycin
may have antitumor activities. He contacted the NCI to
test rapamycin in order to confirm his suspicion. His
research was made even more poignant as his employer
made a management decision that practically shut down
his research on rapamycin. After several years of inactivity,
rapamycin research was resurrected when Wyeth and
Ayerst merged and the company leadership was convinced
by the promising results from animal testing to continue
funding rapamycin therapeutic development.
The NCI’s Developmental Therapeutics Program [50]
was established by Congress in 1955 as the Cancer
Chemotherapy National Service Center to provide pre-
clinical data on compounds that the NCI solicits from
government laboratories, academic institutions, and in-
dustry [49]. These compounds include both synthetic
chemicals (140,000) and natural products (80,000). Of all
the compounds screened by this program, approximately
40% originated from industry. Research from DTP has
led to anticancer drugs that are in use today. For ex-
ample, Paclitaxel was discovered as a natural product
from Yew trees and developed for clinical use for breast
and other types of cancer [9]. Recently, DTP research
led to the development of eribulin mesilate as a micro-
tubule inhibitor for metastatic breast cancer [51], and
FDA approval was issued in 2010. DTP has been suc-
cessful in producing more than 40 U.S. licensed che-
motherapeutic drugs. Many of these have been produced
in collaboration with the commercial sector. The Evero-
limus clinical trial sponsored by Novartis is the transla-
tional product of privately- and federally-funded basic
research on rapamycin and the PI3K/Akt/mTOR signal-
ing. This is another example that illustrates the partner-
ship between the federal government and the industrial
partners that is the cornerstone of clinical translational
research.
Another NIH program that facilitates small molecule
screening is the Molecular Library Screening Centers
Network (MLSCN), established in 2008, to provide
large-scale screening capacity necessary to identify small
molecules that can be optimized as chemical probes to
study the functions of genes, cells, and biochemical
pathways in health and disease. These small molecules
may be used by researchers in the public and private
sectors to validate new drug targets, which could then
move into the drug-development pipeline. The first ex-
ample of successful translation resulting from small mol-
ecule screening to Phase I clinical trial was the
identification of Sphingosine-1-phosphate receptor. This
receptor and related molecules were identified from re-
search conducted by the Scripps Research Institute as
part of the molecular library program. These small
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vate entity, Receptors, Inc., for potential treatment for
multiple sclerosis [52]. It is hoped, through continuing
collaborations among preclinical and clinical investiga-
tors in both the public and private sectors, that breast
cancer therapeutics will continue to be developed based
on the molecular mechanism of the disease. The en-
hancement of the armamentarium for breast cancer
should continue to reduce the mortality and morbidity
for patients.
Conclusion
The story of rapamycin illustrates the need for basic dis-
covery research and the elucidation of biological
mechanisms to inform translation to clinical research
and clinical trials. It may take decades to unravel the full
complexity of biological systems. Basic and translational
research is typically funded by the government. How-
ever, there is an important role for public-private part-
nership in research, especially as it advances to clinical
trials as described in this report.
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